Archives of Pharmacal Research

, Volume 38, Issue 7, pp 1281–1298 | Cite as

Interactions between herbs and antidiabetics: an overview of the mechanisms, evidence, importance, and management

  • Shaheed Ur Rehman
  • Min Sun Choi
  • Kevin Choe
  • Hye Hyun Yoo


Complementary and alternative therapies are quickly gaining importance because they are perceived to be free of side effects due to their natural origin. However, herbal remedies are complex mixtures of bioactive entities, which may interact with prescription drugs through pharmacokinetic or pharmacodynamic mechanisms and sometimes result in life-threatening consequences. In particular, diabetes patients are often treated with multiple medications due to different comorbidities, and such patients use antidiabetic medications for their entire lives; thus, it is important to make the public aware of herb interactions with antidiabetic drugs. In this paper, we summarize the reports available on the interaction of herbal remedies with oral hypoglycemic agents and describe mechanisms, preclinical or clinical evidence, importance, and management strategies.


Herb–drug interaction Antidiabetics Mechanism Evidence Management 



This work was supported by the research fund of Hanyang University (HY-2013-G).


  1. Actos (Pioglitazone hydrochloride). 2011. UK summary of product characteristics. London: Takeda Ltd.Google Scholar
  2. Ahmed, M., A. Alamgeer, T. Sharif, C.H. Zabta, and A. Akbar. 2009. Effect of Berberis lycium Royle on lipid profile in alloxan induced diabetic rabbits. Ethnobotanical Leaflets 13: 702–708.Google Scholar
  3. Ahn, E.K., J.A. Lee, D.W. Seo, S.S. Hong, and J.S. Oh. 2011. 1β-Hydroxy-2-oxopomolic acid isolated from Agrimonia pilosa extract inhibits adipogenesis in 3T3-L1 cells. Biological & Pharmaceutical Bulletin 35: 643–649.Google Scholar
  4. Akhtar, M. 1982. Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes. The Journal of the Pakistan Medical Association 32: 106–107.PubMedGoogle Scholar
  5. Al-Ali, M., S. Wahbi, H. Twaij, and A. Al-Badr. 2003. Tribulus terrestris: Preliminary study of its diuretic and contractile effects and comparison with Zea mays. Journal of Ethnopharmacology 85: 257–260.PubMedGoogle Scholar
  6. Ali, M.A., H.A. Sagar, M.C.S. Khatun, A.K. Azad, K. Begum, and M.I.I. Wahed. 2012. Antihyperglycemic and analgesic activities of ethanolic extract of Cassia fistula (L.) stem bark. International Journal of Pharmaceutical Sciences and Research 3: 416–423.Google Scholar
  7. Amacher, D.E. 2010. The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicology Mechanisms and Methods 20: 159–166.PubMedGoogle Scholar
  8. Anderson, G.D., G. Rosito, M.A. Mohustsy, and G.W. Elmer. 2003. Drug interaction potential of soy extract and Panax ginseng. The Journal of Clinical Pharmacology 43: 643–648.PubMedGoogle Scholar
  9. Anthony, J.B., and C.M. Gregory. Pharmacology Weekly. Retrieved June 2014, from
  10. Appiah-Opong, R., J.N. Commandeur, C. Axson, and N.P. Vermeulen. 2008. Interactions between cytochromes P450, glutathione S-transferases and Ghanaian medicinal plants. Food and Chemical Toxicology 46: 3598–3603.PubMedGoogle Scholar
  11. Arold, G., F. Donath, A. Maurer, K. Diefenbach, S. Bauer, H.H. Henneicke-Von Zepelin, M. Friede, and I. Roots. 2005. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John’s wort extract. Planta Medica 71: 331–337.PubMedGoogle Scholar
  12. Asdaq, S.M.B., and M.N. Inamdar. 2010. Pharmacodynamic interaction of captopril with garlic in isoproterenol-induced myocardial damage in rat. Phytotherapy Research 24: 720–725.PubMedGoogle Scholar
  13. Aslam, M., and I. Stockley. 1979. Interaction between curry ingredient (karela) and drug (chlorpropamide). The Lancet 313: 607.Google Scholar
  14. Baldwa, V., C. Bhandari, A. Pangaria, and R. Goyal. 1977. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Upsala Journal of Medical Sciences 82: 39–41.PubMedGoogle Scholar
  15. Beckert, B.W., M.J. Concannon, S.L. Henry, D.S. Smith, and C.L. Puckett. 2007. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plastic and Reconstructive Surgery 120: 2044–2050.PubMedGoogle Scholar
  16. Bent, S., H. Goldberg, A. Padula, and A.L. Avins. 2005. Spontaneous bleeding associated with Ginkgo biloba. Journal of General Internal Medicine 20: 657–661.PubMedCentralPubMedGoogle Scholar
  17. Bertram, G.K. 2012. Basic and clinical pharmacology. New York: Editorial Mc Graw Hill.Google Scholar
  18. Borhanuddin, M., M. Shamsuzzoha, and A.H. Hussain. 1994. Hypoglycemia effects of Andrographis paniculata Nees on non-diabetic rabbits. Bangladesh Medical Research Council Bulletin 20: 2–24.Google Scholar
  19. Boullata, J. 2005. Natural health product interactions with medication. Nutrition in Clinical Practice 20: 33–51.PubMedGoogle Scholar
  20. Brown, L., O. Heyneke, D. Brown, J. Van Wyk, and J. Hamman. 2008. Impact of traditional medicinal plant extracts on antiretroviral drug absorption. Journal of Ethnopharmacology 119: 588–592.PubMedGoogle Scholar
  21. Budzinski, J., B. Foster, S. Vandenhoek, and J. Arnason. 2000. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7: 273–282.PubMedGoogle Scholar
  22. Budzinski, J.W., V.L. Trudeau, C.E. Drouin, M. Panahi, J.T. Arnason, and B.C. Foster. 2007. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products This article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products. Canadian Journal of Physiology and Pharmacology 85: 966–978.PubMedGoogle Scholar
  23. Bunyapraphatsara, N., S. Yongchaiyudha, V. Rungpitarangsi, and O. Chokechaijaroenporn. 1996. Antidiabetic activity of Aloe vera L. juice II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomedicine 3: 245–248.PubMedGoogle Scholar
  24. Butterweck, V., and H. Derendorf. 2008. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clinical Pharmacokinetics 47: 383–397.PubMedGoogle Scholar
  25. Cermak, R., and S. Wolffram. 2006. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Current Drug Metabolism 7: 729–744.PubMedGoogle Scholar
  26. Chan, N.N., S.E. Baldeweg, T.M. Tan, and S.J. Hurel. 2001. Glucosamine sulphate and osteoarthritis. The Lancet 357: 1618–1619.Google Scholar
  27. Chatterjee, P., and M.R. Franklin. 2003. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metabolism and Disposition 31: 1391–1397.PubMedGoogle Scholar
  28. Caughey, G.E., E.E. Roughead, A.I. Vitry, R.A. McDermott, S. Shakib, and A.L. Gilbert. 2010. Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. Diabetes Research and Clinical Practice 87: 385–393.PubMedGoogle Scholar
  29. Chavez, M.L., M.A. Jordan, and P.I. Chavez. 2006. Evidence-based drug–herbal interactions. Life Sciences 78: 2146–2157.PubMedGoogle Scholar
  30. Chen, W.C., S. Hayakawa, T. Yamamoto, H.C. Su, I.M. Liu, and J.T. Cheng. 2004. Mediation of β-endorphin by the isoflavone puerarin to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Medica 70: 113–116.PubMedGoogle Scholar
  31. Choi, J.S., B.W. Jo, and Y.C. Kim. 2004. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. European Journal of Pharmaceutics and Biopharmaceutics 57: 313–318.PubMedGoogle Scholar
  32. Cho, W., W.S. Chung, S.K. Lee, A.W. Leung, C.H. Cheng, and K.K. Yue. 2006. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. European Journal of Pharmacology 550: 173–179.PubMedGoogle Scholar
  33. Choi, H.C., S.J. Kim, K.Y. Son, B.J. Oh, and B.L. Cho. 2013. Metabolic effects of aloe vera gel complex in obese prediabetes and early non-treated diabetic patients: Randomized controlled trial. Nutrition 29: 1110–1114.PubMedGoogle Scholar
  34. Choudhary, M., A. Kochhar, and J. Sangha. 2014. Hypoglycemic and hypolipidemic effect of Aloe vera L. in non-insulin dependent diabetics. Journal of Food Science and Technology 51: 90–96.PubMedCentralPubMedGoogle Scholar
  35. Cordero-Herrera, I., M.A. Martín, L. Bravo, L. Goya, and S. Ramos. 2013. Cocoa flavonoids improve insulin signalling and modulateglucose production via AKT and AMPK in HepG2 cells. Molecular Nutrition and Food Research 57: 974–985.Google Scholar
  36. Crosby, E.C., R.L. Dolan, J.E. Benson, M.J. Luetkemeier, R.G. Barton, and E.W. Askew. 2001. Herbal diuretic induced dehydration and resting metabolic rate. Medicine and Science in Sports and Exercise 33: S163.Google Scholar
  37. Daisy, P., K. Balasubramanian, M. Rajalakshmi, J. Eliza, and J. Selvaraj. 2010. Insulin mimetic impact of Catechin isolated from Cassia fistula on the glucose oxidation and molecular mechanisms of glucose uptake on streptozotocin-induced diabetic Wistar rats. Phytomedicine 17: 28–36.PubMedGoogle Scholar
  38. Dans, A.M., M.V. Villarruz, C.A. Jimeno, M.A. Javelosa, J. Chua, R. Bautista, and G.G. Velez. 2007. The effect of Momordica charantia capsule preparation on glycemic control in Type 2 diabetes mellitus needs further studies. Journal of Clinical Epidemiology 60: 554–559.PubMedGoogle Scholar
  39. Dasgupta, A., L. Kidd, B.J. Poindexter, and R.J. Bick. 2010. Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin. Archives of Pathology and Laboratory Medicine 134: 1188–1192.PubMedGoogle Scholar
  40. Derosa, G., P. Maffioli, S. At Salvadeo, I. Ferrari, A. Gravina, R. Mereu, A. D’angelo, I. Palumbo, S. Randazzo, and A. Fg Cicero. 2010a. Sibutramine and l-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Internal Medicine 49: 1717–1725.PubMedGoogle Scholar
  41. Derosa, G., P. Maffioli, I. Ferrari, A. D’angelo, E. Fogari, I. Palumbo, S. Randazzo, and A. Cicero. 2010b. Orlistat and l-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocrine Journal 57: 777.PubMedGoogle Scholar
  42. Djuv, A., and O.G. Nilsen. 2012. Aloe vera juice: IC50 and dual mechanistic inhibition of CYP3A4 and CYP2D6. Phytotherapy Research 26: 445–451.PubMedGoogle Scholar
  43. Dusane, M.B., and B.N. Joshi. 2013. Beneficial effect of flax seeds in streptozotocin (STZ) induced diabetic mice: isolation of active fraction having islet regenerative and glucosidase inhibitory properties. Canadian Journal of Physiology and Pharmacology 91: 325–331.PubMedGoogle Scholar
  44. Etheridge, A.S., S.R. Black, P.R. Patel, J. So, and J.M. Mathews. 2007. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Medica 73: 731–741.PubMedGoogle Scholar
  45. Fan, L., X.Q. Mao, G.Y. Tao, G. Wang, F. Jiang, Y. Chen, Q. Li, W. Zhang, H.P. Lei, and D.L. Hu. 2009a. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 39: 249–254.PubMedGoogle Scholar
  46. Fan, L., G.Y. Tao, G. Wang, Y. Chen, W. Zhang, Y.J. He, Q. Li, H.P. Lei, F. Jiang, and D.L. Hu. 2009b. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Annals of Pharmacotherapy 43: 944–949.PubMedGoogle Scholar
  47. Fan, L., G. Zhou, D. Guo, Y.L. Liu, W.Q. Chen, Z.Q. Liu, Z.R. Tan, D. Sheng, H.H. Zhou, and W. Zhang. 2011. The pregnane X receptor agonist St. John’s Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics 50: 605–611.PubMedGoogle Scholar
  48. Fetrow, C.W., J.R. Avila, C.W. Fetrow, 1999. Fetrow, and Avila professional’s handbook of complementary and alternative medicines. Springhouse, PA: Springhouse Corporation.Google Scholar
  49. Foster, B.C., M.S. Foster, S. Vandenhoek, A. Krantis, J.W. Budzinski, J.T. Arnason, K.D. Gallicano, and S. Choudri. 2001. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4: 176–184.PubMedGoogle Scholar
  50. Fu, L.X., H.S. Xia, G. Lu, L.Y. Xiang, and B.X. Hui. 2006. Puerarin protects rat pancreatic islets from damage by hydrogen peroxide. European Journal of Pharmacology 529: 1–7.Google Scholar
  51. Gaede, P., H. Lund-Andersen, H.H. Parving, and O. Pedersen. 2008. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 358: 580–591.PubMedGoogle Scholar
  52. Gaudineau, C., R. Beckerman, S. Welbourn, and K. Auclair. 2004. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochemical and Biophysical Research Communications 318: 1072–1078.PubMedGoogle Scholar
  53. Gilbert, G.J. 1997. Ginkgo biloba. Neurology 48: 1137-1137.Google Scholar
  54. Goey, A.K., I. Meijerman, H. Rosing, S. Marchetti, M. Mergui-Roelvink, M. Keessen, J.A. Burgers, J.H. Beijnen, and J.H. Schellens. 2014. The effect of St. John’s Wort on the pharmacokinetics of docetaxel. Clinical Pharmacokinetics 53: 103–110.PubMedGoogle Scholar
  55. Gonzalez-Ortiz, M., S.O. Hernandez-Gonzalez, E. Hernández-Salazar, and E. Martínez-Abundis. 2008. Effect of oral l-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients. Annals of Nutrition & Metabolism 52: 335–338.Google Scholar
  56. Gorski, J.C., S.M. Huang, A. Pinto, M.A. Hamman, J.K. Hilligoss, N.A. Zaheer, M. Desai, M. Miller, and S.D. Hall. 2004. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clinical Pharmacology and Therapeutics 75: 89–100.PubMedGoogle Scholar
  57. Gray, A.M., Y.H. Abdel-Wahab, and P.R. Flatt. 2000. The traditional plant treatment, Sambucus nigra (elder), exhibits insulin-like and insulin-releasing actions in vitro. The Journal of Nutrition 130: 15–20.PubMedGoogle Scholar
  58. Gray, A.M., and P.R. Flatt. 1997. Pancreatic and extra-pancreatic effects of the traditional anti-diabetic plant, Medicago sativa (lucerne). British Journal of Nutrition 78: 325–334.PubMedGoogle Scholar
  59. Gray, A.M., and P.R. Flatt. 1998. Actions of the traditional anti-diabetic plant, Agrimony eupatoria (agrimony): effects on hyperglycaemia, cellular glucose metabolism and insulin secretion. British Journal of Nutrition 80: 109–114.PubMedGoogle Scholar
  60. Greenblatt, D.J., L.L. Moltke, Y. Luo, E.S. Perloff, K.A. Horan, A. Bruce, R.C. Reynolds, J.S. Harmatz, B. Avula, and I.A. Khan. 2006. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450‐2C9 substrate. The Journal of Clinical Pharmacology 46: 214–221.PubMedGoogle Scholar
  61. Guo, Y.J., D.L. Liang, Z.S. Xu, and Q. Ye. 2014. In vivo inhibitory effects of puerarin on selected rat cytochrome P450 isoenzymes. Die Pharmazie-An International Journal of Pharmaceutical Sciences 69: 367–370.Google Scholar
  62. Gurley, B.J., S.F. Gardner, M.A. Hubbard, D.K. Williams, W.B. Gentry, I.A. Khan, and A. Shah. 2005. In vivo effects of Goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clinical Pharmacology and Therapeutics 77: 415–426.PubMedCentralPubMedGoogle Scholar
  63. Gurley, B.J., A. Swain, M.A. Hubbard, D.K. Williams, G. Barone, F. Hartsfield, Y. Tong, D.J. Carrier, S. Cheboyina, and S.K. Battu. 2008. Clinical assessment of CYP2D6-mediated herb–drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s Wort, and Echinacea. Molecular Nutrition & Food Research 52: 755–763.Google Scholar
  64. Hafner-Blumenstiel, V. 2011. Herbal drug–drug interaction and adverse drug reactions. Therapeutische Umschau. Revue Thérapeutique 68: 54.PubMedGoogle Scholar
  65. Hannan, J., L. Marenah, L. Ali, B. Rokeya, P. Flatt, and Y. Abdel-Wahab. 2006. Ocimum sanctum leaf extracts stimulate insulin secretion from perfused pancreas, isolated islets and clonal pancreatic β-cells. Journal of Endocrinology 189: 127–136.PubMedGoogle Scholar
  66. Hellum, B.H., Z. Hu, and O.G. Nilsen. 2007. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic & Clinical Pharmacology & Toxicology 100: 23–30.Google Scholar
  67. Hikino, H., M. Takahashi, K. Otake, and C. Konno. 1986. Isolation and hypoglycemic activity of eleutherans A, B, C, D, E, F, and G: Glycans of Eleutherococcus senticosus roots. Journal of Natural Products 49: 293–297.PubMedGoogle Scholar
  68. Hiratsuka, M. 2012. In vitro assessment of the allelic variants of cytochrome P450. Drug Metabolism and Pharmacokinetics 27: 68–84.PubMedGoogle Scholar
  69. Hou, X.L., K. Takahashi, N. Kinoshita, F. Qiu, K. Tanaka, K. Komatsu, K. Takahashi, and J. Azuma. 2007. Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1α, 25 dihydroxyvitamin D-3 treated Caco-2 cells. International Journal of Pharmaceutics 337: 169–177.PubMedGoogle Scholar
  70. Hruska, M., J. Cheong, T. Langaee, and R. Frye. 2005. Effect of St. John’s Wort administration on CYP2C8 mediated rosiglitazone metabolism. Clinical Pharmacology and Therapeutics 77: P35.Google Scholar
  71. Hsu, F.L., I.M. Liu, D.H. Kuo, W.C. Chen, H.C. Su, and J.T. Cheng. 2003. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. Journal of Natural Products 66: 788–792.PubMedGoogle Scholar
  72. Hulin, A., M. Wavelet, and J. Desbordes. 1988. Intoxication aiguë par Momordica charantia (Sorrossi)(à propos de deux cas). Médecine d’Afrique Noire 35: 671–674.Google Scholar
  73. Isnard Bagnis, C., G. Deray, A. Baumelou, M. Le Quintrec, and J.L. Vanherweghem. 2004. Herbs and the kidney. American Journal of Kidney Diseases 44: 1–11.PubMedGoogle Scholar
  74. Izzo, A.A., and E. Ernst. 2009. Interactions between herbal medicines and prescribed drugs. Drugs 69: 1777–1798.PubMedGoogle Scholar
  75. Jain, R.K., and J.C. Mccormick. 2004. Can glucosamine supplements be applied for all patients with type 2 diabetes with osteoarthritis? Archives of Internal Medicine 164: 807.PubMedGoogle Scholar
  76. Jellin, J., P. Gregory, F. Batz, and R. Bonakdar. 2014. Natural medicines comprehensive database. Stockton, CA: Therapeutic Research Faculty.Google Scholar
  77. Jiang, X., E.Y. Blair, and A.J. Mclachlan. 2006. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: A population pharmacokinetic-pharmacodynamic modeling approach. The Journal of Clinical Pharmacology 46: 1370–1378.PubMedGoogle Scholar
  78. Kang, M.H., and H.M. Park. 2010. Hypertension after ingestion of baked garlic (Allium sativum) in a dog. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science 72: 515.PubMedGoogle Scholar
  79. Karyekar, C., N. Eddington, and T. Dowling. 2002. Effect of St. John’s Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells. Journal of Postgraduate Medicine 48: 97.PubMedGoogle Scholar
  80. Khanna, P., S. Jain, A. Panagariya, and V. Dixit. 1981. Hypoglycemic activity of polypeptide-p from a plant source. Journal of Natural Products 44: 648–655.PubMedGoogle Scholar
  81. Kim, B.H., K.P. Kim, K.S. Lim, J.R. Kim, S.H. Yoon, J.Y. Cho, Y.O. Lee, K.H. Lee, I.J. Jang, and S.G. Shin. 2010. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: An open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clinical Therapeutics 32: 380–390.PubMedGoogle Scholar
  82. Kim, D.Y., H.D. Yuan, I.K. Chung, and S.H. Chung. 2009. Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. Journal of Agricultural and Food Chemistry 57: 1532–1537.Google Scholar
  83. Kim, H.Y., and K. Kim. 2012. Regulation of signaling molecules associated with insulin action, insulin secretion and pancreatic β-cell mass in the hypoglycemic effects of Korean red ginseng in Goto-Kakizaki rats. Journal of Ethnopharmacology 142: 53–58.PubMedGoogle Scholar
  84. Kim, I.S., S.Y. Kim, and H.H. Yoo. 2012. Effects of an aqueous-ethanolic extract of ginger on cytochrome P450 enzyme-mediated drug metabolism. Pharmazie 67: 1007–1009.PubMedGoogle Scholar
  85. Kim, K.A., P.W. Park, H.K. Kim, J.M. Ha, and J.Y. Park. 2005. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. The Journal of Clinical Pharmacology 45: 941–946.PubMedGoogle Scholar
  86. Kober, M., K. Pohl, and T. Efferth. 2008. Molecular Mechanisms Underlying St. Johns wort Drug Interactions. Current Drug Metabolism 9: 1027–1037.PubMedGoogle Scholar
  87. Komoroski, B.J., R.A. Parise, M.J. Egorin, S.C. Strom, and R. Venkataramanan. 2005. Effect of the St. John’s wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clinical Cancer Research 11: 6972–6979.PubMedGoogle Scholar
  88. Kuhn, M.A. 2002. Herbal remedies: Drug–herb interactions. Critical Care Nurse 22: 22–32.PubMedGoogle Scholar
  89. Lai, D.M., Y.K. Tu, I.M. Liu, and J.T. Cheng. 2006. Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Medica 72: 9–13.PubMedGoogle Scholar
  90. Lam, A.Y., G.W. Elmer, and M.A. Mohutsky. 2001. Possible interaction between warfarin and Lycium barbarum L. Annals of Pharmacotherapy 35: 1199–1201.PubMedGoogle Scholar
  91. Langhammer, A.J., and O.G. Nilsen. 2014. In vitro Inhibition of Human CYP1A2, CYP2D6, and CYP3A4 by six herbs commonly used in pregnancy. Phytotherapy Research 28: 603–610.PubMedGoogle Scholar
  92. Leatherdale, B., R. Panesar, G. Singh, T. Atkins, C. Bailey, and A. Bignell. 1981. Improvement in glucose tolerance due to Momordica charantia (karela). British Medical Journal (Clinical Research ed.) 282: 1823.Google Scholar
  93. Lee, M.S., J.T. Hwang, S.H. Kim, S. Yoon, M.S. Kim, H.J. Yang, and D.Y. Kwon. 2010. Ginsenoside Rc, an active component of Panax ginseng, stimulates glucose uptake in C2C12 myotubes through an AMPK-dependent mechanism. Journal of Ethnopharmacology 127: 771–776.PubMedGoogle Scholar
  94. Lee, S.H., S.W. Lim, Y.M. Lee, H.S. Lee, and D.K. Kim. 2012. Polysaccharide isolated from Triticum aestivum stimulates insulin release from pancreatic cells via the ATP-sensitive K+ channel. International Journal of Molecular Medicine 29: 913.PubMedGoogle Scholar
  95. Lee, W.K., S.T. Kao, I.M. Liu, and J.T. Cheng. 2006. Increase of insulin secretion by ginsenoside Rh2 to lower plasma glucose in Wistar rats. Clinical and Experimental Pharmacology and Physiology 33: 27–32.PubMedGoogle Scholar
  96. Li, W., M. Zhang, V.J. Gu, Z.J. Meng, L.C. Zhao, Y.N. Zheng, L. Chen, and G.L. Yang. 2012. Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound K on Type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis. Fitoterapia 83: 192–198.PubMedGoogle Scholar
  97. Liu, C., M. Zhang, M.Y. Hu, H.F. Guo, J. Li, Y.L. Yu, S. Jin, X.T. Wang, L. Liu, and X.D. Liu. 2013a. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. Journal of Endocrinology 217: 185–196.PubMedGoogle Scholar
  98. Liu, Z., W. Li, X. Li, M. Zhang, L. Chen, Y.N. Zheng, G.Z. Sun, and C.C. Ruan. 2013b. Antidiabetic effects of malonyl ginsenosides from Panax ginseng on type 2 diabetic rats induced by high-fat diet and streptozotocin. Journal of Ethnopharmacology 145: 233–240.PubMedGoogle Scholar
  99. Luo, Q., Y. Cai, J. Yan, M. Sun, and H. Corke. 2004. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum. Life Sciences 76: 137–149.PubMedGoogle Scholar
  100. Ma, X., C. Zheng, L. Han, B. Xie, J. Jia, Z. Cao, Y. Li, and Y. Chen. 2009. Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. Drug Discovery Today 14: 579–588.PubMedGoogle Scholar
  101. Madabushi, R., B. Frank, B. Drewelow, H. Derendorf, and V. Butterweck. 2006. Hyperforin in St. John’s wort drug interactions. European Journal of Clinical Pharmacology 62: 225–233.PubMedGoogle Scholar
  102. Malati, C.Y., S.M. Robertson, J.D. Hunt, C, Chairez, R.M. Alfaro, J.A. Kovacs, and S.R. Penzak. 2012. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. Journal of Clinical Pharmacology 52:932–939.Google Scholar
  103. Malpani, S.N., K.P. Manjunath, H. Sholapur, R.V. Savadi, K.S. Akki, and S.S. Darade. 2010. Antidiabetic activity of Cassia fistula Linn. bark in alloxan induced diabetic rats. International Journal of Pharmaceutical Sciences and Research 2: 382–385.Google Scholar
  104. Marchetti, S., R. Mazzanti, J.H. Beijnen, and J.H. Schellens. 2007. Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 12: 927–941.PubMedGoogle Scholar
  105. Matsuda, K., Y. Nishimura, N. Kurata, M. Iwase, and H. Yasuhara. 2007. Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat. Journal of Pharmacological Sciences 103: 214–221.PubMedGoogle Scholar
  106. Meijerman, I., J.H. Beijnen, and J.H. Schellens. 2006. Herb–drug interactions in oncology: Focus on mechanisms of induction. The Oncologist 11: 742–752.PubMedGoogle Scholar
  107. Menegazzi, M., M. Novelli, P. Beffy, V. D’Aleo, E. Tedeschi, R. Lupi, E. Zoratti, P. Marchetti, H. Suzuki, and P. Masiello. 2008. Protective effects of St. John’s wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic β-cell line. The International Journal of Biochemistry and Cell Biology 40: 1509–1521.PubMedGoogle Scholar
  108. Mingrone, G., A.V. Greco, E. Capristo, G. Benedetti, A. Giancaterini, A.D. Gaetano, and G. Gasbarrini. 1999. l-Carnitine improves glucose disposal in type 2 diabetic patients. Journal of the American College of Nutrition 18: 77–82.PubMedGoogle Scholar
  109. Mohutsky, M.A., G.D. Anderson, J.W. Miller, and G.W. Elmer. 2006. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. American Journal of Therapeutics 13: 24–31.PubMedGoogle Scholar
  110. Moltke, L.L., J.L. Weemhoff, E. Bedir, I.A. Khan, J.S. Harmatz, P. Goldman, and D.J. Greenblatt. 2004. Inhibition of human cytochromes P450 by components of Ginkgo biloba. Journal of Pharmacy and Pharmacology 56: 1039–1044.Google Scholar
  111. Moore, L.B., B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, T.M. Willson, J.L. Collins, and S.A. Kliewer. 2000. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proceedings of the National Academy of Sciences 97: 7500–7502.Google Scholar
  112. Muhammad, I., R. Afza, and S. Yousaf. 2006. Ethnopharmacological survey of plants used for the treatment of stomach, diabetes, and ophthalmic diseases in Sudhan Gali, Kashmir, Pakistan. Acta Botanica Yunnanica 28: 535–542.Google Scholar
  113. Narendhirakannan, R., S. Subramanian, and M. Kandaswamy. 2006. Biochemical evaluation of antidiabetogenic properties of some commonly used Indian plants on streptozotocin-induced diabetes in experimental rats. Clinical and Experimental Pharmacology and Physiology 33: 1150–1157.PubMedGoogle Scholar
  114. National Institutes of Health Office of Dietary Supplements. 2013. Botanical dietary supplements: Background information. Retrieved, from
  115. Nebert, D.W., and D.W. Russell. 2002. Clinical importance of the cytochromes P450. The Lancet 360: 1155–1162.Google Scholar
  116. Nirmala, A., I. Eliza, M. Rajalakshmi, E. Priya, and P. Daisy. 2008. Effect of hexane extract of Cassia fstula barks on blood glucose and lipid profile in streptozotocin diabetic rats. International Journal of Pharmacology 4: 292–296.Google Scholar
  117. Nivitabishekam, S.N., M. Asad, and V.S. Prasad. 2009. Pharmacodynamic interaction of Momordica charantia with rosiglitazone in rats. Chemico-Biological Interactions 177: 247–253.PubMedGoogle Scholar
  118. Norlin, M., and K. Wikvall. 2007. Enzymes in the conversion of cholesterol into bile acids. Current Molecular Medicine 7: 199–218.PubMedGoogle Scholar
  119. Nowack, R. 2008. Cytochrome P450 enzyme, and transport protein mediated herb–drug interactions in renal transplant patients: Grapefruit juice, St. John’s wort—and beyond! Nephrology 13: 337–347.PubMedGoogle Scholar
  120. Obach, R.S. 2000. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s wort, an herbal preparation used in the treatment of depression. Journal of Pharmacology and Experimental Therapeutics 294: 88–95.PubMedGoogle Scholar
  121. Ono, S., T. Hatanaka, H. Hotta, T. Satoh, F. Gonzalez, and M. Tsutsui. 1996. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26: 681–693.PubMedGoogle Scholar
  122. Ooi, J.P., M. Kuroyanagi, S.F. Sulaiman, T.S.T. Muhammad, and M.L. Tan. 2011. Andrographolide and 14-deoxy-11, 12-didehydroandrographolide inhibit cytochrome P450s in HepG2 hepatoma cells. Life Sciences 88: 447–454.PubMedGoogle Scholar
  123. Pan, Y., B.A. Abd-Rashid, Z. Ismail, R. Ismail, J.W. Mak, P.C. Pook, H.M. Er, and C.E. Ong. 2011a. In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). Journal of Ethnopharmacology 133: 881–887.PubMedGoogle Scholar
  124. Pan, Y., B.A. Abd-Rashid, Z. Ismail, R. Ismail, J.W. Mak, P.C. Pook, H.M. Er, and C.E. Ong. 2011b. In vitro determination of the effect of Andrographis paniculata extracts and andrographolide on human hepatic cytochrome P450 activities. Journal of Natural Medicines 65: 440–447.PubMedGoogle Scholar
  125. Persiani, S., L. Canciani, P. Larger, R. Rotini, G. Trisolino, D. Antonioli, and L. Rovati. 2009. In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate. Drug Metabolism and Drug Interactions 24: 195–210.PubMedGoogle Scholar
  126. Qiu, F., G. Wang, R. Zhang, J. Sun, J. Jiang, and Y. Ma. 2010. Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. British Journal of Clinical Pharmacology 69: 656–662.PubMedCentralPubMedGoogle Scholar
  127. Qiu, F., R. Zhang, J. Sun, A. Jiye, H. Hao, Y. Peng, H. Ai, and G. Wang. 2008. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metabolism and Disposition 36: 1308–1314.PubMedGoogle Scholar
  128. Rahbar, A., R. Shakerhosseini, N. Saadat, F. Taleban, A. Pordal, and B. Gollestan. 2005. Effect of l-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus. European Journal of Clinical Nutrition 59: 592–596.PubMedGoogle Scholar
  129. Raman, A., and C. Lau. 1996. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine 2: 349–362.PubMedGoogle Scholar
  130. Ratnasooriya, W.D., J.R. Jayakody, and H.D. Hettiarachchi. 2004. Cassia fistula and hypoglycaemia. Australian Journal of Medical Herbalism 16: 8.Google Scholar
  131. Raza, H., I. Ahmed, A. John, and A.K. Sharma. 2000. Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with Momordica charantia fruit extract. Journal of Biochemical and Molecular Toxicology 14: 131–139.PubMedGoogle Scholar
  132. Raza, H., I. Ahmed, M.S. Lakhani, A.K. Sharma, D. Pallot, and W. Montague. 1996. Effect of bitter melon (Momordica Charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochemical Pharmacology 52: 1639–1642.PubMedGoogle Scholar
  133. Reyes, B., N. Bautista, N. Tanquilut, R. Anunciado, A. Leung, G. Sanchez, R. Magtoto, P. Castronuevo, H. Tsukamura, and K.I. Maeda. 2006. Anti-diabetic potentials of Momordica charantia and Andrographis paniculata and their effects on estrous cyclicity of alloxan-induced diabetic rats. Journal of Ethnopharmacology 105: 196–200.PubMedGoogle Scholar
  134. Richard, A.J., Z.J. Amini, D.M. Ribnicky, and J.M. Stephens. 2012. St. John’s wort inhibits insulin signaling in murine and human adipocytes. Biochimica et Biophysica Acta (BBA) 1822: 557–563.Google Scholar
  135. Rowin, J., and S.L. Lewis. 1996. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 46: 1775–1776.PubMedGoogle Scholar
  136. Samson, R. 1982. Effects of dietary garlic and temporal drift on platelet aggregation. Atherosclerosis 44: 119–120.PubMedGoogle Scholar
  137. Scott, G.N., and G.W. Elmer. 2002. Update on natural product–drug interactions. American Journal of Health-system Pharmacy 59: 339–347.PubMedGoogle Scholar
  138. Scroggie, D.A., A. Albright, and M.D. Harris. 2003. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized clinical trial. Archives of Internal Medicine 163: 1587.PubMedGoogle Scholar
  139. Sen, S., M.A. Querques, and S. Chakrabarti. 2013. North American Ginseng (Panax quinquefolius) prevents hyperglycemia and associated pancreatic abnormalities in diabetes. Journal of Medicinal Food 16: 587–592.PubMedGoogle Scholar
  140. Singh, K.N., and U.R. Bharadwaj. 1975. Hypoglycaemic activity of Albizzia stipulata, Albizzia moluccana and Cassia fistula leguminous seed diets on normal young rats. Indian Journal of Pharmacology 7: 47.Google Scholar
  141. Skalli, S., A. Zaid, and R. Soulaymani. 2007. Drug interactions with herbal medicines. Therapeutic Drug Monitoring 29: 679–686.PubMedGoogle Scholar
  142. Smith, M., K. Lin, and Y. Zheng. 2001. An open trial of nifedipine-herb interactions: Nufedipine with St. John’s wort, Ginseng or Ginko biloba. Clinical Pharmacology & Therapeutics, P86–P86. St. Louis: Mosby, Inc.Google Scholar
  143. Solimene, U., A. Alkofahi, C. Allemann, M. Amigoni, R. Aspan, S. Azimova, B.C. Bloodworth, G. Caccialanza, A. Caizzi, and M. Cheraghali. 2007. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues.Google Scholar
  144. Srivastava, Y., H. Venkatakrishna-Bhatt, Y. Verma, K. Venkaiah, and B. Raval. 1993. Antidiabetic and adaptogenic properties of Momordica charantia extract: An experimental and clinical evaluation. Phytotherapy Research 7: 285–289.Google Scholar
  145. Sugiyama, T., Y. Kubota, K. Shinozuka, S. Yamada, K. Yamada, and K. Umegaki. 2004a. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food and Chemical Toxicology 42: 953–957.PubMedGoogle Scholar
  146. Sugiyama, T., J.I. Nagata, A. Yamagishi, K. Endoh, M. Saito, K. Yamada, S. Yamada, and K. Umegaki. 2006. Selective protection of curcumin against carbon tetrachloride-induced inactivation of hepatic cytochrome P450 isozymes in rats. Life Sciences 78: 2188–2193.PubMedGoogle Scholar
  147. Sugiyama, T., K. Shinozuka, A. Sano, S. Yamada, K. Endoh, K. Yamada, and K. Umegaki. 2004b. Effects of various Ginkgo biloba extracts and proanthocyanidin on hepatic cytochrome P450 activity in rats. Journal of the Food Hygienic Society of Japan 45: 295.PubMedGoogle Scholar
  148. Sun, C., Y. Chen, X. Li, G. Tai, Y. Fan, and Y. Zhou. 2014. Anti-hyperglycemic and anti-oxidative activities of ginseng polysaccharides in STZ-induced diabetic mice. Food and Function 5: 845–848.PubMedGoogle Scholar
  149. Sun, H., Z. Zuo, O. Yin, B. Tomlinson, and M. Chow. 2002. A “high-throughput” cocktail method for screening the effect of herbal product on liver isozyme activities: Experience with Ginkgo biloba. Clinical Pharmacology & Therapeutics 71: P100–P100.Google Scholar
  150. Swanston, S.K., C. Day, C. Bailey, and P. Flatt. 1990. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetologia 33: 462–464.Google Scholar
  151. Tachjian, A., V. Maria, and A. Jahangir. 2010. Use of herbal products and potential interactions in patients with cardiovascular diseases. Journal of the American College of Cardiology 55: 515–525.PubMedCentralPubMedGoogle Scholar
  152. Tarirai, C., A.M. Viljoen, and J.H. Hamman. 2010. Herb–drug pharmacokinetic interactions reviewed. Expert Opinion on Drug Metabolism and Toxicology 6: 1515–1538.PubMedGoogle Scholar
  153. Tiwari, J.K., L.R. Dangwal, C.S. Rana, P. Tiwari, and R. Ballabha. 2010. Indigenous uses of plant species in Nanda Devi Biosphere Reserve, Uttarakhand, India. Report and Opinion 2: 58–61.Google Scholar
  154. Tongia, A., S.K. Tongia, and M. Dave. 2004. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian Journal of Physiology and Pharmacology 48: 241–244.PubMedGoogle Scholar
  155. Tseng-Crank, J., S.G. Do, B. Corneliusen, C. Hertel, J. Homan, M. Yimam, J. Zhao, and Q. Jia. 2013. UP780, A chromone-enriched aloe composition, enhances adipose insulin receptor signaling and decreases liver lipid biosynthesis. Open Journal of Genetics 3: 9.Google Scholar
  156. Uchida, S., H. Yamada, X.D. Li, S. Maruyama, Y. Ohmori, T. Oki, H. Watanabe, K. Umegaki, K. Ohashi, and S. Yamada. 2006. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. The Journal of Clinical Pharmacology 46: 1290–1298.PubMedGoogle Scholar
  157. Unger, M., and A. Frank. 2004. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Communications in Mass Spectrometry 18: 2273–2281.PubMedGoogle Scholar
  158. Vale, S. 1998. Subarachnoid haemorrhage associated with Ginkgo biloba. The Lancet 352: 36.Google Scholar
  159. Van Dam, R. 2006. Coffee and type 2 diabetes: From beans to beta-cells. Nutrition, Metabolism and Cardiovascular Diseases 16: 69–77.PubMedGoogle Scholar
  160. Van den Bout‐Van Den Beukel, C.J., J. Carolien, O.J. Hamza, M.J. Moshi, M.I. Matee, F. Mikx, D.M. Burger, P.P. Koopmans, P.E. Verweij, and W.G. Schoonen. 2008. Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infections. Basic and Clinical Pharmacology and Toxicology 102: 515–526.PubMedGoogle Scholar
  161. Van Dam, R.M., W.J. Pasman, and P. Verhoef. 2004. Effects of coffee consumption on fasting blood glucose and insulin concentrations randomized controlled trials in healthy volunteers. Diabetes Care 27: 2990–2992.PubMedGoogle Scholar
  162. Virdi, J., S. Sivakami, S. Shahani, A. Suthar, M. Banavalikar, and M. Biyani. 2003. Antihyperglycemic effects of three extracts from Momordica charantia. Journal of Ethnopharmacology 88: 107–111.PubMedGoogle Scholar
  163. Vuksan, V., J.L. Sievenpiper, V.Y. Koo, T. Francis, U. Beljan-Zdravkovic, Z. Xu, and E. Vidgen. 2000a. American ginseng (Panax quinquefolius L.) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Archives of Internal Medicine 160: 1009.PubMedGoogle Scholar
  164. Vuksan, V., M.P. Stavro, J.L. Sievenpiper, U. Beljan-Zdravkovic, L.A. Leiter, R.G. Josse, and Z. Xu. 2000b. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care 23: 1221–1226.PubMedGoogle Scholar
  165. Vuksan, V., M.P. Stavro, J.L. Sievenpiper, V.Y. Koo, E. Wong, U. Beljan-Zdravkovic, T. Francis, A.L. Jenkins, L.A. Leiter, and R.G. Josse. 2000c. American ginseng improves glycemia in individuals with normal glucose tolerance: Effect of dose and time escalation. Journal of the American College of Nutrition 19: 738–744.PubMedGoogle Scholar
  166. Vuksan, V., M.K. Sung, J.L. Sievenpiper, P.M. Stavro, A.L. Jenkins, M. Di Buono, K.S. Lee, L.A. Leiter, K.Y. Nam, and J.T. Arnason. 2008. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: Results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism and Cardiovascular Diseases 18: 46–56.PubMedGoogle Scholar
  167. Walker, B.R., N.R. Colledge, S.H. Ralston, and I. Penman. 2013. Davidson’s principles and practice of medicine. New York: Elsevier.Google Scholar
  168. Walker, P.S., and J.A. Donovan. 1999. Herbal remedies: Natural caveats. International Journal of Dermatology 38: 746–748.PubMedGoogle Scholar
  169. Wang, J.F., and K.C. Chou. 2010. Molecular modeling of cytochrome P450 and drug metabolism. Current Drug Metabolism 11: 342–346.PubMedGoogle Scholar
  170. Wang, Z., J.C. Gorski, M.A. Hamman, S.M. Huang, L.J. Lesko, and S.D. Hall. 2001. The effects of St. John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70: 317–326.PubMedGoogle Scholar
  171. Welihinda, J., E. Karunanayake, M. Sheriff, and K. Jayasinghe. 1986. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. Journal of Ethnopharmacology 17: 277–282.PubMedGoogle Scholar
  172. Whiting, D.R., L. Guariguata, C. Weil, and J. Shaw. 2011. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice 94: 311–321.PubMedGoogle Scholar
  173. Whitten, D., S. Myers, J. Hawrelak, and H. Wohlmuth. 2006. The effect of St. John’s wort extracts on CYP3A: A systematic review of prospective clinical trials. British Journal of Clinical Pharmacology 62: 512–526.PubMedCentralPubMedGoogle Scholar
  174. Williamson, E.M., S. Driver, K. Baxter, and C.R. Lee. 2013. Stockley’s herbal medicines interactions. London: Pharmaceutical Press.Google Scholar
  175. Xiong, Y., L. Shen, K.J. Liu, P. Tso, Y. Xiong, G. Wang, S.C. Woods, and M. Liu. 2010. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats. Diabetes 59: 2505–2512.PubMedCentralPubMedGoogle Scholar
  176. Xu, H., K. Williams, W. Liauw, M. Murray, R. Day, and A. Mclachlan. 2008. Effects of St. John’s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology 153: 1579–1586.PubMedCentralPubMedGoogle Scholar
  177. Yagi, A. 2014. Possible efficacy of aloe vera gel metabolites in long-term ingestion to insulin sensitivity. Journal of Gastroenterology and Hepatology Research 3: 996-1005.Google Scholar
  178. Yale, S.H., and I. Glurich. 2005. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. Journal of Alternative and Complementary Medicine 11: 433–439.PubMedGoogle Scholar
  179. Yeleswaram, K., N. Vachharajani, and K. Santone. 1999. Involvement of cytochrome P-450 isozymes in melatonin metabolism and clinical implications. Journal of Pineal Research 26: 190–191.PubMedGoogle Scholar
  180. Yimam, M., J. Zhao, B. Corneliusen, M. Pantier, L. Brownell, and Q. Jia. 2014. Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mice diabetes model. Diabetology and Metabolic Syndrome 6: 61.PubMedCentralPubMedGoogle Scholar
  181. Yimam, M., J. Zhao, B. Corneliusen, M. Pantier, L.A. Brownell, and Q. Jia. 2013. UP780, a chromone-enriched aloe composition improves insulin sensitivity. Metabolic Syndrome and Related Disorders 11: 267–275.PubMedGoogle Scholar
  182. Yin, O.Q., B. Tomlinson, M.M. Waye, A.H. Chow, and M.S. Chow. 2004. Pharmacogenetics and herb–drug interactions: Experience with Ginkgo biloba and omeprazole. Pharmacogenetics and Genomics 14: 841–850.Google Scholar
  183. Yongchaiyudha, S., V. Rungpitarangsi, N. Bunyapraphatsara, and O. Chokechaijaroenporn. 1996. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus. Phytomedicine 3: 241–243.PubMedGoogle Scholar
  184. Yoo, K.M., C. Lee, Y.M. Lo, and B. Moon. 2012. The hypoglycemic effects of American red ginseng (Panax quinquefolius L.) on a diabetic mouse model. Journal of Food Science 77: H147–H152.PubMedGoogle Scholar
  185. Yoo, H.H., M.W. Lee, Y.C. Kim, C.H. Yun, and D.H. Kim. 2007. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica gigas. Drug Metabolism and Disposition 35: 1759–1765.PubMedGoogle Scholar
  186. Yoo, H.H., S.H. Lee, C. Jin, and D.H. Kim. 2008. Mechanism-based inactivation of cytochrome P450 3A4 by methylenedioxyphenyl lignans from Acanthopanax chiisanensis. Planta Medica 74: 808–813.Google Scholar
  187. Yu, B.C., W.C. Chen, and J.T. Cheng. 2003a. Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats. Planta Medica 69: 1075–1079.PubMedGoogle Scholar
  188. Yu, C., Y.G. Shin, J.W. Kosmeder, J.M. Pezzuto, and R.B. van Breemen. 2003b. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Communications in Mass Spectrometry 17: 307–313.PubMedGoogle Scholar
  189. Zhang, X.F., and B.K. Tan. 2000. Antihyperglycemic and anti-oxidant properties of Andrographis paniculata in normal and diabetic rats. Clinical and Experimental Pharmacology and Physiology 27: 358–363.PubMedGoogle Scholar
  190. Zhao, R., Q. Li, and B. Xiao. 2005. Effect of Lycium barbarum polysaccharide on the improvement of insulin resistance in NIDDM rats. Yakugaku Zasshi 125: 981–988.PubMedGoogle Scholar
  191. Zhong, Z., C. Wang, W. Wang, L. Shen, and Z. Chen. 2014. Major hypoglycemic ingredients of panax notoginseng saponins for treating diabetes. Journal of Sichuan University (Medical Science Edition) 45: 235–239.Google Scholar
  192. Zhou, S.F., and X. Lai. 2008. An Update on Clinical Drug Interactions with the Herbal Antidepressant St. John’s wort. Current Drug Metabolism 9: 394–409.PubMedGoogle Scholar
  193. Zou, L., M. Harkey, and G. Henderson. 2002. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sciences 71: 1579–1589.PubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2014

Authors and Affiliations

  • Shaheed Ur Rehman
    • 1
  • Min Sun Choi
    • 1
  • Kevin Choe
    • 1
  • Hye Hyun Yoo
    • 1
  1. 1.Institute of Pharmaceutical Science and Technology and College of PharmacyHanyang UniversityAnsanRepublic of Korea

Personalised recommendations